Combined-modality therapy of locally advanced non-small-cell lung cancer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Treatment of patients with unresectable stage IIIA and IIIB non-small- cell lung cancer with conventionally-fractionated radiation therapy (ie, total doses of 50 to 60 Gy, using one fraction per day), which was standard practice in the 1970s and early 1980s, resulted in good short-term palliation but few long-term survivors. Local control was poor, and the majority of patients also rapidly developed symptomatic metastatic disease outside the chest. In the past 15 years, a number of approaches to improve this situation have been defined in prospective clinical trials. They include radiation therapy with altered fractionation schemes that allow either higher overall doses or shortened treatment times, the use of systemic chemotherapy to address microscopic metastatic disease, and the use of a variety of agents, some but not all with intrinsic cytotoxic activity, to act as radiation sensitizers. These strategies have resulted in modest but significant improvements in local and systemic disease control, but at a cost of increased toxicity, including myelosuppression, esophagitis, and pneumonitis. Further advances in treatment will require better (ie, more active) cytotoxic agents and better ways of limiting radiation effects to the target volume of tumor.

Original languageEnglish (US)
Pages (from-to)43-50
Number of pages8
JournalONCOLOGY
Volume11
Issue number9 SUPPL.
StatePublished - Oct 16 1997

Fingerprint

Combined Modality Therapy
Non-Small Cell Lung Carcinoma
Radiotherapy
Radiation-Sensitizing Agents
Esophagitis
Radiation Effects
Cytotoxins
Tumor Burden
Survivors
Pneumonia
Thorax
Therapeutics
Clinical Trials
Costs and Cost Analysis
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{d02bad7985b94a9183669463b09e60bb,
title = "Combined-modality therapy of locally advanced non-small-cell lung cancer",
abstract = "Treatment of patients with unresectable stage IIIA and IIIB non-small- cell lung cancer with conventionally-fractionated radiation therapy (ie, total doses of 50 to 60 Gy, using one fraction per day), which was standard practice in the 1970s and early 1980s, resulted in good short-term palliation but few long-term survivors. Local control was poor, and the majority of patients also rapidly developed symptomatic metastatic disease outside the chest. In the past 15 years, a number of approaches to improve this situation have been defined in prospective clinical trials. They include radiation therapy with altered fractionation schemes that allow either higher overall doses or shortened treatment times, the use of systemic chemotherapy to address microscopic metastatic disease, and the use of a variety of agents, some but not all with intrinsic cytotoxic activity, to act as radiation sensitizers. These strategies have resulted in modest but significant improvements in local and systemic disease control, but at a cost of increased toxicity, including myelosuppression, esophagitis, and pneumonitis. Further advances in treatment will require better (ie, more active) cytotoxic agents and better ways of limiting radiation effects to the target volume of tumor.",
author = "{Wagner Jr.}, Henry",
year = "1997",
month = "10",
day = "16",
language = "English (US)",
volume = "11",
pages = "43--50",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "9 SUPPL.",

}

Combined-modality therapy of locally advanced non-small-cell lung cancer. / Wagner Jr., Henry.

In: ONCOLOGY, Vol. 11, No. 9 SUPPL., 16.10.1997, p. 43-50.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combined-modality therapy of locally advanced non-small-cell lung cancer

AU - Wagner Jr., Henry

PY - 1997/10/16

Y1 - 1997/10/16

N2 - Treatment of patients with unresectable stage IIIA and IIIB non-small- cell lung cancer with conventionally-fractionated radiation therapy (ie, total doses of 50 to 60 Gy, using one fraction per day), which was standard practice in the 1970s and early 1980s, resulted in good short-term palliation but few long-term survivors. Local control was poor, and the majority of patients also rapidly developed symptomatic metastatic disease outside the chest. In the past 15 years, a number of approaches to improve this situation have been defined in prospective clinical trials. They include radiation therapy with altered fractionation schemes that allow either higher overall doses or shortened treatment times, the use of systemic chemotherapy to address microscopic metastatic disease, and the use of a variety of agents, some but not all with intrinsic cytotoxic activity, to act as radiation sensitizers. These strategies have resulted in modest but significant improvements in local and systemic disease control, but at a cost of increased toxicity, including myelosuppression, esophagitis, and pneumonitis. Further advances in treatment will require better (ie, more active) cytotoxic agents and better ways of limiting radiation effects to the target volume of tumor.

AB - Treatment of patients with unresectable stage IIIA and IIIB non-small- cell lung cancer with conventionally-fractionated radiation therapy (ie, total doses of 50 to 60 Gy, using one fraction per day), which was standard practice in the 1970s and early 1980s, resulted in good short-term palliation but few long-term survivors. Local control was poor, and the majority of patients also rapidly developed symptomatic metastatic disease outside the chest. In the past 15 years, a number of approaches to improve this situation have been defined in prospective clinical trials. They include radiation therapy with altered fractionation schemes that allow either higher overall doses or shortened treatment times, the use of systemic chemotherapy to address microscopic metastatic disease, and the use of a variety of agents, some but not all with intrinsic cytotoxic activity, to act as radiation sensitizers. These strategies have resulted in modest but significant improvements in local and systemic disease control, but at a cost of increased toxicity, including myelosuppression, esophagitis, and pneumonitis. Further advances in treatment will require better (ie, more active) cytotoxic agents and better ways of limiting radiation effects to the target volume of tumor.

UR - http://www.scopus.com/inward/record.url?scp=9844239914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9844239914&partnerID=8YFLogxK

M3 - Article

C2 - 9330408

AN - SCOPUS:9844239914

VL - 11

SP - 43

EP - 50

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 9 SUPPL.

ER -